Zydus Cadila gets USFDA nod for cancer medication

On Friday, Zydus Cadila announced that it has received final approval from United States Food & Drug Administration to market Erlotinib tablets (US RLD: Tarceva tablets), in the strengths of 25 mg, 100 mg and 150 mg.

Erlotinib is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is also used to treat non-small cell lung cancer or pancreatic cancer that has spread to other parts of the body (metastatic). It is a drug usually administered after other cancer medicines have been tried but in vain.

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ. The group now has 288 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare Limited manufactures and markets healthcare solutions ranging from formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. Its products are available in tablets, capsules, injections, liquids, dry syrups, powders, granules and ointments.

On Friday, the stock closed at Rs 333.75, down by 2.85 per cent or Rs 8.80 per share. The 52-week high is recorded at Rs 378 and the 52-week low is Rs 206.45 on BSE.